Research Progress of Traditional Chinese Medicine Monomers in Reversing Multidrug Resistance of Breast Cancer

Author:

Wang Shuya1,Yang Shuangyu1,Yang Xiaojia2,Deng Dan3,Li Jie1,Dong Mingqing1

Affiliation:

1. Cancer Prevention and Treatment Institute of Chengdu, Center for Medicine Research and Translation, Chengdu Fifth People’s Hospital/The Second Clinical Medical College, The Affiliated Fifth People’s Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 611137, P. R. China

2. Clinical Trial Unit, Chengdu Fifth People’s Hospital/The Second Clinical Medical College, The Affiliated Fifth People’s Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 611137, P. R. China

3. Department of Pathology Chengdu Fifth People’s Hospital/The Second Clinical Medical College, The Affiliated Fifth People’s Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 611137, P. R. China

Abstract

Breast cancer is a malignant disease with an increasing incidence. Chemotherapy is still an important means for breast cancer treatment, but multidrug resistance (MDR) greatly limits its clinical application. Therefore, the high-efficiency MDR reversal agents are urgently needed. Traditional Chinese medicine (TCM) monomers have unique advantages in reversing chemotherapeutic MDR because of its low toxicity, high efficiency, and ability to impact multiple targets. This review firstly summarizes the major mechanisms of MDR in breast cancer, including the reduced accumulation of intracellular chemotherapeutic drugs, the promoted inactivation of intracellular chemotherapeutic drugs, and the enhanced damage repair ability of DNA, etc., and secondly highlights the research progress of 15 kinds of TCM monomers, including curcumin, resveratrol, emodin, apigenin, tetrandrine, gambogic acid, matrine, paeonol, schisandrin B, [Formula: see text]-elemene, astragaloside IV, berberine, puerarin, tanshinone IIA, and quercetin, in reversing MDR of breast cancer. This review also provides the suggestion for the future research of MDR reversal agents in breast cancer.

Funder

the Chengdu and Science Technology Bureau Project

the Chengdu Municipal Health Commission Project

the Chengdu High-level Key Clinical Specialty Construction Project

Xinglin Scholars Program of Chengdu University of Traditional Chinese Medicine

the Natural Science Foundation of Sichuan Province

Publisher

World Scientific Pub Co Pte Ltd

Subject

Complementary and alternative medicine,General Medicine

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3